Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O15117
UPID:
FYB1_HUMAN
Alternative names:
Adhesion and degranulation promoting adaptor protein; FYB-120/130; FYN-T-binding protein; SLAP-130; SLP-76-associated phosphoprotein
Alternative UPACC:
O15117; A8K2Y8; B4DLN2; E9PBV9; O00359; Q9NZI9
Background:
FYN-binding protein 1, known by alternative names such as Adhesion and degranulation promoting adaptor protein and SLAP-130, plays a crucial role in T-cell signaling, actin cytoskeleton remodeling, and platelet activation. It acts as an adapter in the FYN and LCP2 signaling cascades and modulates IL2 expression, essential for immune response regulation.
Therapeutic significance:
Linked to Thrombocytopenia 3, a disorder characterized by a reduced platelet count leading to increased bleeding risks, FYN-binding protein 1's involvement in platelet activation and immune signaling pathways presents a promising target for therapeutic intervention in hematologic disorders.